Slide 1: Fiscal 2023 year to date results
Fiscal 2023 year to date results (nine months ended March 31, 2023) Ron Delia CEO Michael Casamento CFO May 2, 2023 US May 3, 2023 Australia NYSE: AMCR | ASX: AMC
Slide 2: Disclaimers
Disclaimers Cautionary Statement Regarding Forward-Looking Statements This document contains certain statements that are “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are generall
Slide 3: Safety
Safety Guided by our values. Our number one priority Recordable-case frequency rate Amcor Values (per million hours worked) 11.2 Includes impact of acquired businesses 4.1 • 23% reduction in number of injuries fiscal 2.0 2.8 2.1 1.6 2023 year to date 0.3 • 64% of sites injury free for >12 months 200
Slide 4: Key messages
Key messages 1. Well positioned with consumer staples and healthcare exposure 2. Not immune from challenging operating environment 3. Decisive actions on price and cost 4. FY23 guidance updated on general market softness 5. Continuing to invest to drive growth and value creation 4
Slide 5: Solid year to date – challenging macro dynamics in Q3
Solid year to date – challenging macro dynamics in Q3 Recovering inflation and managing costs in a soft and volatile demand environment 3Q23 YTD 3Q23 Net sales $11,021m +2% $3,667m +1% • ~$745 million cash returns to Net sales (+9% including 7% pass through of (+3% including 2% pass through of share
Slide 6: Decisive action on price and cost
Decisive action on price and cost Proactively managing the controllables 3Q Adjusted EBIT 2.5% lower Actions taken 1. Lower volumes with increased 1. Pricing to compensate for inflation: volatility ~$1bn YTD 2. Mix trending unfavorably 2. Cost productivity and flexing: 3. Ongoing cost inflation ~$14
Slide 7: Flexibles segment
Flexibles segment Solid sales growth and cost focus 3Q22 3Q23 Comparable FY2023 YTD highlights constant YTD YTD currency • Net sales of $8.4bn includes price increases of ~$490m Net sales ($m) 8,184 8,378 +3% (6% growth) related to higher raw material costs • Net sales up 3%. Strong price/mix; volum
Slide 8: Rigid Packaging segment
Rigid Packaging segment More volatile demand and unfavorable mix trends 3Q22 3Q23 Comparable FY2023 YTD highlights constant YTD YTD currency • Net sales of $2.6bn include price increases of ~$260m Net sales ($m) 2,451 2,643 (2)% (11% growth) from higher raw material costs • North America: Adjusted E
Slide 9: Cash flow and balance sheet
Cash flow and balance sheet Strong, investment grade balance sheet. Focus on inventory reductions Year to date cash flow ($ million) 3Q22 3Q23 FY2023 YTD highlights Adjusted EBITDA 1,507 1,478 • Strong, investment grade balance sheet Interest and tax payments (235) (299) • Working capital impacted b
Slide 10: Fiscal 2023 guidance - updated
Fiscal 2023 guidance - updated Adjusted EPS Guidance 80.5 • Updated FY23 adjusted EPS reflects: cps • Demand environment in Q4 expected to remain In line ~2% 72-74 soft with heightened volatility. Overall volumes (~4%) cps expected to be down mid-single digits (~3%) (~4%) • Estimated net interest ex
Slide 11: Investing in multiple drivers of sustainable organic growth
Investing in multiple drivers of sustainable organic growth Priority Emerging Innovation Categories Markets >$4 bn sales in higher growth, >$3 bn Emerging Markets sales Driving value through higher value categories: across 27 countries: differentiated packaging: Healthcare Protein Hot-fill beverage
Slide 12: Value creating M&A
Value creating M&A Long history of successful execution and a deep pipeline of opportunities Effective M&A model Value Creating Acquisitions to supplement organic growth Strategy led Financial discipline Ample capacity Flexible packaging MDK - Medical Moda Systems - Machinery plant in Czech packagin
Slide 13: Recognition for progress against our sustainability agenda
Recognition for progress against our sustainability agenda 2023 winner in Food, Health Recognizing Amcor’s 5 Consecutive Years & Personal Care and Medical ongoing sustainability identified as a leader in and Pharmaceutical commitment and responsible packaging and categories achievements ESG topics A
Slide 14: Key messages
Key messages 1. Well positioned with consumer staples and healthcare exposure 2. Not immune from challenging operating environment 3. Decisive actions on price and cost 4. FY23 guidance updated on general market softness 5. Continuing to invest to drive growth and value creation 14
Slide 15: Appendix slides
Appendix slides Supplementary schedules and reconciliations
Slide 16: Strong foundation for growth & value creation
Strong foundation for growth & value creation Global leader in primary packaging for consumer staples and healthcare with a strong track record Consistent growth from priority categories, emerging markets and innovation Strong cash flow and balance sheet provide ongoing capacity to invest Increasing
Slide 17: FX translation impact
FX translation impact Nine months ended March 31, 2023 Combined Net income currency currency impact exposures(1) Total currency impact $ million Adjusted EBIT (40) EUR 20-30% Adjusted Net income (33) EUR:USD Euro weakened vs USD, Average USD million impact on USD to EUR rate 3Q23 0.9687 vs 3Q23 adju
Slide 18: Reconciliations of non-GAAP financial measures
Reconciliations of non-GAAP financial measures 18
Slide 19: Reconciliations of non-GAAP financial measures
Reconciliations of non-GAAP financial measures 19
Slide 20: Reconciliations of non-GAAP financial measures
Reconciliations of non-GAAP financial measures 20
Slide 21: Reconciliations of non-GAAP financial measures
Reconciliations of non-GAAP financial measures 21
Slide 22: Reconciliations of non-GAAP financial measures
Reconciliations of non-GAAP financial measures 22